SK9142000A3 - Tetrahydro isoquinolinyl carboxamide compounds, preparation thereof, pharmaceutical composition containing them and their use - Google Patents

Tetrahydro isoquinolinyl carboxamide compounds, preparation thereof, pharmaceutical composition containing them and their use Download PDF

Info

Publication number: SK9142000A3
Authority: SK; Slovakia
Prior art keywords: disorders; methoxy; tetraisoquinolin; chloro; alkyl
Prior art date: 1997-12-17

Application number

SK914-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Steven Coulton

Roderick Alan Porter

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-17

Filing date

1998-12-16

Publication date

2000-11-07

1998-12-16 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2000-11-07 Publication of SK9142000A3 publication Critical patent/SK9142000A3/sk

Links

-1 Tetrahydro isoquinolinyl carboxamide compounds Chemical class 0.000 title claims abstract description 30
238000002360 preparation method Methods 0.000 title claims description 19
239000008194 pharmaceutical composition Substances 0.000 title claims description 4
150000001875 compounds Chemical class 0.000 claims abstract description 75
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 58
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 33
208000035475 disorder Diseases 0.000 claims abstract description 32
239000001257 hydrogen Substances 0.000 claims abstract description 31
230000001537 neural effect Effects 0.000 claims abstract description 27
201000010099 disease Diseases 0.000 claims abstract description 26
239000000126 substance Substances 0.000 claims abstract description 26
208000004296 neuralgia Diseases 0.000 claims abstract description 23
150000003839 salts Chemical class 0.000 claims abstract description 23
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims abstract description 20
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims abstract description 19
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims abstract description 19
201000006417 multiple sclerosis Diseases 0.000 claims abstract description 19
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
150000002431 hydrogen Chemical class 0.000 claims abstract description 15
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 14
150000002367 halogens Chemical class 0.000 claims abstract description 13
238000011282 treatment Methods 0.000 claims abstract description 13
239000001961 anticonvulsive agent Substances 0.000 claims abstract description 12
229910052736 halogen Inorganic materials 0.000 claims abstract description 12
230000035939 shock Effects 0.000 claims abstract description 12
239000012453 solvate Substances 0.000 claims abstract description 12
208000019901 Anxiety disease Diseases 0.000 claims abstract description 11
206010026749 Mania Diseases 0.000 claims abstract description 11
230000036506 anxiety Effects 0.000 claims abstract description 11
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 10
208000030507 AIDS Diseases 0.000 claims abstract description 10
206010003591 Ataxia Diseases 0.000 claims abstract description 10
206010058019 Cancer Pain Diseases 0.000 claims abstract description 10
206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 10
208000019695 Migraine disease Diseases 0.000 claims abstract description 10
208000002740 Muscle Rigidity Diseases 0.000 claims abstract description 10
208000008238 Muscle Spasticity Diseases 0.000 claims abstract description 10
208000002193 Pain Diseases 0.000 claims abstract description 10
208000018737 Parkinson disease Diseases 0.000 claims abstract description 10
206010036312 Post-traumatic epilepsy Diseases 0.000 claims abstract description 10
208000028017 Psychotic disease Diseases 0.000 claims abstract description 10
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims abstract description 10
208000009205 Tinnitus Diseases 0.000 claims abstract description 10
230000016571 aggressive behavior Effects 0.000 claims abstract description 10
229940049706 benzodiazepine Drugs 0.000 claims abstract description 10
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims abstract description 10
229960003920 cocaine Drugs 0.000 claims abstract description 10
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 10
230000000694 effects Effects 0.000 claims abstract description 10
206010015037 epilepsy Diseases 0.000 claims abstract description 10
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims abstract description 10
206010022437 insomnia Diseases 0.000 claims abstract description 10
206010027599 migraine Diseases 0.000 claims abstract description 10
208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 10
230000007971 neurological deficit Effects 0.000 claims abstract description 10
229960002715 nicotine Drugs 0.000 claims abstract description 10
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims abstract description 10
208000019906 panic disease Diseases 0.000 claims abstract description 10
201000000980 schizophrenia Diseases 0.000 claims abstract description 10
208000019116 sleep disease Diseases 0.000 claims abstract description 10
208000018198 spasticity Diseases 0.000 claims abstract description 10
231100000886 tinnitus Toxicity 0.000 claims abstract description 10
208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims abstract description 9
208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 9
208000016620 Tourette disease Diseases 0.000 claims abstract description 9
208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 9
201000003631 narcolepsy Diseases 0.000 claims abstract description 9
208000021722 neuropathic pain Diseases 0.000 claims abstract description 9
230000009529 traumatic brain injury Effects 0.000 claims abstract description 9
206010043220 Temporomandibular joint syndrome Diseases 0.000 claims abstract description 8
125000001424 substituent group Chemical group 0.000 claims abstract description 8
208000024827 Alzheimer disease Diseases 0.000 claims abstract description 7
206010044652 trigeminal neuralgia Diseases 0.000 claims abstract description 6
125000002837 carbocyclic group Chemical group 0.000 claims abstract description 4
229920006395 saturated elastomer Polymers 0.000 claims abstract description 4
208000026072 Motor neurone disease Diseases 0.000 claims abstract description 3
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims abstract description 3
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
125000002950 monocyclic group Chemical group 0.000 claims abstract description 3
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims abstract 2
125000000217 alkyl group Chemical group 0.000 claims description 37
238000000034 method Methods 0.000 claims description 30
125000000304 alkynyl group Chemical group 0.000 claims description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
SWXSODIZVQALAJ-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-1-carboxamide Chemical class C1=CC=C2C(C(=O)N)NCCC2=C1 SWXSODIZVQALAJ-UHFFFAOYSA-N 0.000 claims description 11
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
201000006474 Brain Ischemia Diseases 0.000 claims description 9
230000001773 anti-convulsant effect Effects 0.000 claims description 9
229940125681 anticonvulsant agent Drugs 0.000 claims description 9
206010008118 cerebral infarction Diseases 0.000 claims description 9
239000000460 chlorine Substances 0.000 claims description 9
230000002265 prevention Effects 0.000 claims description 9
230000033764 rhythmic process Effects 0.000 claims description 9
201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 8
125000003342 alkenyl group Chemical group 0.000 claims description 8
239000003814 drug Substances 0.000 claims description 7
125000006124 n-propyl sulfonyl group Chemical group 0.000 claims description 7
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 6
229910052801 chlorine Inorganic materials 0.000 claims description 6
239000012458 free base Substances 0.000 claims description 6
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 6
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 6
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 5
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
229910052794 bromium Chemical group 0.000 claims description 5
229910052740 iodine Inorganic materials 0.000 claims description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 claims description 4
GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 4
RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 4
229910004013 NO 2 Inorganic materials 0.000 claims description 4
239000011737 fluorine Substances 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 4
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 4
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
229940124597 therapeutic agent Drugs 0.000 claims description 3
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 2
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
BGTOWKSIORTVQH-HOSYLAQJSA-N cyclopentanone Chemical group O=[13C]1CCCC1 BGTOWKSIORTVQH-HOSYLAQJSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
230000004064 dysfunction Effects 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
208000005264 motor neuron disease Diseases 0.000 claims description 2
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
210000003901 trigeminal nerve Anatomy 0.000 claims description 2
DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical group CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims 1
235000005544 Acinos arvensis Nutrition 0.000 claims 1
244000207178 Acinos arvensis Species 0.000 claims 1
241000282465 Canis Species 0.000 claims 1
208000034189 Sclerosis Diseases 0.000 claims 1
125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 claims 1
239000004081 narcotic agent Substances 0.000 claims 1
230000002981 neuropathic effect Effects 0.000 claims 1
125000005010 perfluoroalkyl group Chemical group 0.000 claims 1
125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
206010008748 Chorea Diseases 0.000 abstract 1
208000017164 Chronobiology disease Diseases 0.000 abstract 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
208000012601 choreatic disease Diseases 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
239000000203 mixture Substances 0.000 description 38
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
239000008186 active pharmaceutical agent Substances 0.000 description 24
239000002904 solvent Substances 0.000 description 19
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 18
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 15
239000007787 solid Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
150000001408 amides Chemical class 0.000 description 11
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
239000012074 organic phase Substances 0.000 description 10
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
210000001519 tissue Anatomy 0.000 description 9
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
206010010904 Convulsion Diseases 0.000 description 7
150000001412 amines Chemical class 0.000 description 7
239000003480 eluent Substances 0.000 description 7
235000019441 ethanol Nutrition 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000007788 liquid Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 5
229910021529 ammonia Inorganic materials 0.000 description 5
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
UCJQSGHEAGPXKG-UHFFFAOYSA-N n-(8-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Cl UCJQSGHEAGPXKG-UHFFFAOYSA-N 0.000 description 5
DUJFIXJYRUOLAR-UHFFFAOYSA-N n-[8-bromo-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C(=O)C(F)(F)F)C2=C1Br DUJFIXJYRUOLAR-UHFFFAOYSA-N 0.000 description 5
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
229910000027 potassium carbonate Inorganic materials 0.000 description 5
239000000725 suspension Substances 0.000 description 5
UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
241000700159 Rattus Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
239000000543 intermediate Substances 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
239000003826 tablet Substances 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
238000010626 work up procedure Methods 0.000 description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
PBKYPTQBAQQVPT-UHFFFAOYSA-N 4-methoxy-3-(trifluoromethyl)benzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1C(F)(F)F PBKYPTQBAQQVPT-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
206010043994 Tonic convulsion Diseases 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
239000012267 brine Substances 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
229920000609 methyl cellulose Polymers 0.000 description 3
239000001923 methylcellulose Substances 0.000 description 3
235000010981 methylcellulose Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
LZXQFYUUMWVPQK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinolin-1-amine Chemical compound C1=CC=C2C(N)NCCC2=C1 LZXQFYUUMWVPQK-UHFFFAOYSA-N 0.000 description 2
HQRZUWHVVHWAOS-UHFFFAOYSA-N 1-(7-amino-8-chloro-3,4-dihydro-1h-isoquinolin-2-yl)-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC2=C(Cl)C(N)=CC=C21 HQRZUWHVVHWAOS-UHFFFAOYSA-N 0.000 description 2
IACALXBFASHNOT-UHFFFAOYSA-N 1-nitro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2C([N+](=O)[O-])NCCC2=C1 IACALXBFASHNOT-UHFFFAOYSA-N 0.000 description 2
VDTUSEIYUROSGJ-UHFFFAOYSA-N 1-nitroisoquinoline Chemical compound C1=CC=C2C([N+](=O)[O-])=NC=CC2=C1 VDTUSEIYUROSGJ-UHFFFAOYSA-N 0.000 description 2
YSICRJMRSUBBED-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-(2-nitrophenyl)ethyl]acetamide Chemical compound [O-][N+](=O)C1=CC=CC=C1CCNC(=O)C(F)(F)F YSICRJMRSUBBED-UHFFFAOYSA-N 0.000 description 2
QBAYIBZITZBSFO-UHFFFAOYSA-N 2-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C(F)(F)F QBAYIBZITZBSFO-UHFFFAOYSA-N 0.000 description 2
YWACQASDNQYYDF-UHFFFAOYSA-N 3-bromo-n-[8-chloro-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-ethoxybenzamide Chemical compound C1=C(Br)C(OCC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C(=O)C(F)(F)F)C2=C1Cl YWACQASDNQYYDF-UHFFFAOYSA-N 0.000 description 2
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
SHSGDXCJYVZFTP-UHFFFAOYSA-N 4-ethoxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C=C1 SHSGDXCJYVZFTP-UHFFFAOYSA-N 0.000 description 2
VNWUPESTVBTYJM-UHFFFAOYSA-N 4-methoxy-3-(trifluoromethyl)benzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1C(F)(F)F VNWUPESTVBTYJM-UHFFFAOYSA-N 0.000 description 2
XABRDGANBUNGIP-UHFFFAOYSA-N 4-methoxy-n-(8-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1C XABRDGANBUNGIP-UHFFFAOYSA-N 0.000 description 2
SAKBCVXSGILYAK-UHFFFAOYSA-N 4-methoxy-n-[8-(2-phenylethenyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1C=CC1=CC=CC=C1 SAKBCVXSGILYAK-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
229940126062 Compound A Drugs 0.000 description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
229930040373 Paraformaldehyde Natural products 0.000 description 2
XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000002082 anti-convulsion Effects 0.000 description 2
229960003965 antiepileptics Drugs 0.000 description 2
238000003556 assay Methods 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
230000027455 binding Effects 0.000 description 2
YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
125000001246 bromo group Chemical group Br* 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019253 formic acid Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
239000011630 iodine Substances 0.000 description 2
AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
JQYMTUWGOAERPU-UHFFFAOYSA-N n-(8-bromo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Br JQYMTUWGOAERPU-UHFFFAOYSA-N 0.000 description 2
ZFLFUPRRTCQSKA-UHFFFAOYSA-N n-(8-ethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=CC=2CCNCC=2C(CC)=C1NC(=O)C1=CC=C(OC)C(C(F)(F)F)=C1 ZFLFUPRRTCQSKA-UHFFFAOYSA-N 0.000 description 2
SDPFHSCHBVYKDP-UHFFFAOYSA-N n-[8-chloro-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C(=O)C(F)(F)F)C2=C1Cl SDPFHSCHBVYKDP-UHFFFAOYSA-N 0.000 description 2
210000005036 nerve Anatomy 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
229920002866 paraformaldehyde Polymers 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
210000004129 prosencephalon Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
208000028500 tonic seizure Diseases 0.000 description 2
TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
YEZPCNZZDHCZDL-UHFFFAOYSA-N 1-(7-amino-3,4-dihydro-1h-isoquinolin-2-yl)-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC2=CC(N)=CC=C21 YEZPCNZZDHCZDL-UHFFFAOYSA-N 0.000 description 1
MFFJLWVBUMKXIZ-UHFFFAOYSA-N 1-(7-amino-8-bromo-3,4-dihydro-1h-isoquinolin-2-yl)-2,2,2-trifluoroethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC2=C(Br)C(N)=CC=C21 MFFJLWVBUMKXIZ-UHFFFAOYSA-N 0.000 description 1
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
UIUVZNDFDIVPBV-UHFFFAOYSA-N 2,2,2-trifluoro-1-(7-nitro-3,4,4a,5-tetrahydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC2=CC([N+](=O)[O-])=CCC21 UIUVZNDFDIVPBV-UHFFFAOYSA-N 0.000 description 1
QNZQGGKAGPRZEE-UHFFFAOYSA-N 2,2,2-trifluoro-1-(7-nitro-3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound C1CN(C(=O)C(F)(F)F)CC2=CC([N+](=O)[O-])=CC=C21 QNZQGGKAGPRZEE-UHFFFAOYSA-N 0.000 description 1
TXKHTPYMJBUBHQ-UHFFFAOYSA-N 2,2,2-trifluoro-n-[2-(4-nitrophenyl)ethyl]acetamide Chemical compound [O-][N+](=O)C1=CC=C(CCNC(=O)C(F)(F)F)C=C1 TXKHTPYMJBUBHQ-UHFFFAOYSA-N 0.000 description 1
JVMHULJEYUQYSH-UHFFFAOYSA-N 2-(4-nitrophenyl)ethylazanium;chloride Chemical compound Cl.NCCC1=CC=C([N+]([O-])=O)C=C1 JVMHULJEYUQYSH-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 1
XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 1
RIKPTLDRVDPEJW-UHFFFAOYSA-N 3-acetyl-4-ethoxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C=C1C(C)=O RIKPTLDRVDPEJW-UHFFFAOYSA-N 0.000 description 1
AUGCUTFURTZKAB-UHFFFAOYSA-N 3-acetyl-4-propan-2-ylbenzoic acid Chemical compound CC(C)C1=CC=C(C(O)=O)C=C1C(C)=O AUGCUTFURTZKAB-UHFFFAOYSA-N 0.000 description 1
YGXWORCCYMWDCN-UHFFFAOYSA-N 3-acetyl-n-(8-bromo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxybenzamide Chemical compound C1=C(C(C)=O)C(OCC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Br YGXWORCCYMWDCN-UHFFFAOYSA-N 0.000 description 1
PLRUQNUDOUVDIX-UHFFFAOYSA-N 3-acetyl-n-(8-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxybenzamide Chemical compound C1=C(C(C)=O)C(OCC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Cl PLRUQNUDOUVDIX-UHFFFAOYSA-N 0.000 description 1
ACHKBFXVIIPBQK-UHFFFAOYSA-N 3-acetyl-n-(8-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-propan-2-yloxybenzamide Chemical compound C1=C(C(C)=O)C(OC(C)C)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Cl ACHKBFXVIIPBQK-UHFFFAOYSA-N 0.000 description 1
SQFVSXNJQURYNX-UHFFFAOYSA-N 3-acetyl-n-[8-bromo-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-ethoxybenzamide Chemical compound C1=C(C(C)=O)C(OCC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C(=O)C(F)(F)F)C2=C1Br SQFVSXNJQURYNX-UHFFFAOYSA-N 0.000 description 1
XCKMWULLKHQZIP-UHFFFAOYSA-N 3-bromo-4-ethoxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C=C1Br XCKMWULLKHQZIP-UHFFFAOYSA-N 0.000 description 1
LQFMXKIGVFPAGJ-UHFFFAOYSA-N 3-bromo-4-ethoxybenzoyl chloride Chemical compound CCOC1=CC=C(C(Cl)=O)C=C1Br LQFMXKIGVFPAGJ-UHFFFAOYSA-N 0.000 description 1
OOYDBPIPVXBMJI-UHFFFAOYSA-N 3-bromo-n-(8-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxybenzamide Chemical compound C1=C(Br)C(OCC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Cl OOYDBPIPVXBMJI-UHFFFAOYSA-N 0.000 description 1
OUKDBHJVSKTZHA-UHFFFAOYSA-N 3-bromo-n-(8-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-methoxybenzamide Chemical compound C1=C(Br)C(OC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Cl OUKDBHJVSKTZHA-UHFFFAOYSA-N 0.000 description 1
DQHQTDVCUZZVBS-UHFFFAOYSA-N 3-bromo-n-(8-chloro-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl)-4-ethoxybenzamide Chemical compound C1=C(Br)C(OCC)=CC=C1C(=O)NC1=CC=C(CCN(C)C2)C2=C1Cl DQHQTDVCUZZVBS-UHFFFAOYSA-N 0.000 description 1
VGMJYTDQPWANJQ-UHFFFAOYSA-N 3-chloro-4-ethoxybenzoic acid Chemical compound CCOC1=CC=C(C(O)=O)C=C1Cl VGMJYTDQPWANJQ-UHFFFAOYSA-N 0.000 description 1
WBTDIGWLLLLBMJ-UHFFFAOYSA-N 3-chloro-n-(8-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-ethoxybenzamide Chemical compound C1=C(Cl)C(OCC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Cl WBTDIGWLLLLBMJ-UHFFFAOYSA-N 0.000 description 1
HCCSFTCLDDNWRP-UHFFFAOYSA-N 4-methoxy-3-(trifluoromethyl)benzamide Chemical compound COC1=CC=C(C(N)=O)C=C1C(F)(F)F HCCSFTCLDDNWRP-UHFFFAOYSA-N 0.000 description 1
NBOIXKFVBOCRRK-UHFFFAOYSA-N 4-methoxy-n-[2-methyl-8-(2-phenylethenyl)-3,4-dihydro-1h-isoquinolin-7-yl]-3-(trifluoromethyl)benzamide;hydrochloride Chemical compound Cl.C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C)C2)C2=C1C=CC1=CC=CC=C1 NBOIXKFVBOCRRK-UHFFFAOYSA-N 0.000 description 1
PLSHVEDNJRDKJE-UHFFFAOYSA-N 4-methoxy-n-[8-(2-phenylethenyl)-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1h-isoquinolin-7-yl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C(=O)C(F)(F)F)C2=C1C=CC1=CC=CC=C1 PLSHVEDNJRDKJE-UHFFFAOYSA-N 0.000 description 1
CSGZGCCMSHKPHS-UHFFFAOYSA-N 4-methoxy-n-[8-methyl-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1h-isoquinolin-7-yl]-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C(=O)C(F)(F)F)C2=C1C CSGZGCCMSHKPHS-UHFFFAOYSA-N 0.000 description 1
PMRSETIJSQHJTO-UHFFFAOYSA-N 5-benzoyl-n-(7-iodo-2-methyl-3,4-dihydro-1h-isoquinolin-5-yl)-2-methoxybenzamide Chemical compound C1=C(C(=O)NC=2C=3CCN(C)CC=3C=C(I)C=2)C(OC)=CC=C1C(=O)C1=CC=CC=C1 PMRSETIJSQHJTO-UHFFFAOYSA-N 0.000 description 1
YPRWYZSUBZXORL-UHFFFAOYSA-N 7-nitro-1,2,3,4-tetrahydroisoquinoline Chemical compound C1CNCC2=CC([N+](=O)[O-])=CC=C21 YPRWYZSUBZXORL-UHFFFAOYSA-N 0.000 description 1
VFTOHJFKIJLYKN-UHFFFAOYSA-N 7-nitro-9h-fluoren-2-ol Chemical compound [O-][N+](=O)C1=CC=C2C3=CC=C(O)C=C3CC2=C1 VFTOHJFKIJLYKN-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
229920000881 Modified starch Polymers 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000002585 base Substances 0.000 description 1
150000003936 benzamides Chemical class 0.000 description 1
150000001559 benzoic acids Chemical class 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000006931 brain damage Effects 0.000 description 1
231100000874 brain damage Toxicity 0.000 description 1
208000029028 brain injury Diseases 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
150000003857 carboxamides Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
238000001816 cooling Methods 0.000 description 1
LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000003818 flash chromatography Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
VGGRCVDNFAQIKO-UHFFFAOYSA-N formic anhydride Chemical compound O=COC=O VGGRCVDNFAQIKO-UHFFFAOYSA-N 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
150000002314 glycerols Chemical class 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
230000002140 halogenating effect Effects 0.000 description 1
208000031169 hemorrhagic disease Diseases 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical group C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
OSILBMSORKFRTB-UHFFFAOYSA-N isoquinolin-1-amine Chemical compound C1=CC=C2C(N)=NC=CC2=C1 OSILBMSORKFRTB-UHFFFAOYSA-N 0.000 description 1
150000002537 isoquinolines Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
ZOGPYKAGBMBZAW-UHFFFAOYSA-N methyl 3-acetyl-4-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC=C(OC(C)C)C(C(C)=O)=C1 ZOGPYKAGBMBZAW-UHFFFAOYSA-N 0.000 description 1
NCJZJVWOEXLSKA-UHFFFAOYSA-N methyl 3-bromo-4-ethoxybenzoate Chemical compound CCOC1=CC=C(C(=O)OC)C=C1Br NCJZJVWOEXLSKA-UHFFFAOYSA-N 0.000 description 1
RKUNSPWAQIUGEZ-UHFFFAOYSA-N methyl 3-bromo-4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C(Br)=C1 RKUNSPWAQIUGEZ-UHFFFAOYSA-N 0.000 description 1
HVUYIEIHXSRIFZ-UHFFFAOYSA-N methyl 3-bromo-4-propan-2-yloxybenzoate Chemical compound COC(=O)C1=CC=C(OC(C)C)C(Br)=C1 HVUYIEIHXSRIFZ-UHFFFAOYSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
235000019426 modified starch Nutrition 0.000 description 1
230000036651 mood Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
ZANGENJVDPXYQH-UHFFFAOYSA-N n-(1,2,3,4-tetrahydroisoquinolin-1-yl)benzamide Chemical class N1CCC2=CC=CC=C2C1NC(=O)C1=CC=CC=C1 ZANGENJVDPXYQH-UHFFFAOYSA-N 0.000 description 1
DEOBZMPAXSKSDG-UHFFFAOYSA-N n-(5-iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-2-(1-methoxydiazirin-3-yl)-4-(trifluoromethyl)benzamide Chemical compound CON1N=C1C1=CC(C(F)(F)F)=CC=C1C(=O)NC1=CC(I)=C(CCNC2)C2=C1 DEOBZMPAXSKSDG-UHFFFAOYSA-N 0.000 description 1
CPOWRYUVKHVCSB-UHFFFAOYSA-N n-(7-iodo-1,2,3,4-tetrahydroisoquinolin-5-yl)-2-(1-methoxydiazirin-3-yl)-5-(trifluoromethyl)benzamide Chemical compound CON1N=C1C1=CC=C(C(F)(F)F)C=C1C(=O)NC1=CC(I)=CC2=C1CCNC2 CPOWRYUVKHVCSB-UHFFFAOYSA-N 0.000 description 1
GZMVVMNVDPTQKA-UHFFFAOYSA-N n-(8-bromo-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl)-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C)C2)C2=C1Br GZMVVMNVDPTQKA-UHFFFAOYSA-N 0.000 description 1
ADGXWQKSLQSHTG-UHFFFAOYSA-N n-(8-chloro-1,2,3,4-tetrahydroisoquinolin-7-yl)-3-fluoro-4-methoxybenzamide Chemical compound C1=C(F)C(OC)=CC=C1C(=O)NC1=CC=C(CCNC2)C2=C1Cl ADGXWQKSLQSHTG-UHFFFAOYSA-N 0.000 description 1
SVZZMAOLYMUYHW-UHFFFAOYSA-N n-(8-chloro-2-formyl-3,4-dihydro-1h-isoquinolin-7-yl)-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C2)C=O)C2=C1Cl SVZZMAOLYMUYHW-UHFFFAOYSA-N 0.000 description 1
NITUSMKXQLFXKI-UHFFFAOYSA-N n-(8-chloro-2-methylsulfonyl-3,4-dihydro-1h-isoquinolin-7-yl)-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(C2)S(C)(=O)=O)C2=C1Cl NITUSMKXQLFXKI-UHFFFAOYSA-N 0.000 description 1
OOYQHZAGXXMCRE-UHFFFAOYSA-N n-(8-ethyl-2-methyl-3,4-dihydro-1h-isoquinolin-7-yl)-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=CC=2CCN(C)CC=2C(CC)=C1NC(=O)C1=CC=C(OC)C(C(F)(F)F)=C1 OOYQHZAGXXMCRE-UHFFFAOYSA-N 0.000 description 1
ACJMARFUYITZPK-UHFFFAOYSA-N n-[8-chloro-2-(2-hydroxyethyl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1C(=O)NC1=CC=C(CCN(CCO)C2)C2=C1Cl ACJMARFUYITZPK-UHFFFAOYSA-N 0.000 description 1
IVNRLXOVYBJFHY-UHFFFAOYSA-N n-[8-ethyl-2-(2,2,2-trifluoroacetyl)-3,4-dihydro-1h-isoquinolin-7-yl]-4-methoxy-3-(trifluoromethyl)benzamide Chemical compound C1=CC=2CCN(C(=O)C(F)(F)F)CC=2C(CC)=C1NC(=O)C1=CC=C(OC)C(C(F)(F)F)=C1 IVNRLXOVYBJFHY-UHFFFAOYSA-N 0.000 description 1
QDDCKSGUPXHJOU-UHFFFAOYSA-N n-phenylnitramide;hydrochloride Chemical compound Cl.[O-][N+](=O)NC1=CC=CC=C1 QDDCKSGUPXHJOU-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
239000003182 parenteral nutrition solution Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
229910000073 phosphorus hydride Inorganic materials 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
CUNPJFGIODEJLQ-UHFFFAOYSA-M potassium;2,2,2-trifluoroacetate Chemical compound [K+].[O-]C(=O)C(F)(F)F CUNPJFGIODEJLQ-UHFFFAOYSA-M 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000000216 proconvulsive effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000003653 radioligand binding assay Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229940071182 stannate Drugs 0.000 description 1
239000001119 stannous chloride Substances 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000007858 starting material Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
238000010998 test method Methods 0.000 description 1
RWWNQEOPUOCKGR-UHFFFAOYSA-N tetraethyltin Chemical compound CC[Sn](CC)(CC)CC RWWNQEOPUOCKGR-UHFFFAOYSA-N 0.000 description 1
VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical class OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
238000009827 uniform distribution Methods 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Other In-Based Heterocyclic Compounds (AREA)

SK914-2000A 1997-12-17 1998-12-16 Tetrahydro isoquinolinyl carboxamide compounds, preparation thereof, pharmaceutical composition containing them and their use SK9142000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9726695.1A GB9726695D0 (en)	1997-12-17	1997-12-17	Novel compounds
PCT/GB1998/003785 WO1999031068A1 (fr)	1997-12-17	1998-12-16	Derives d'isoquinoline substituee et utilisation de ces derniers comme anticonvulsifs

Publications (1)

Publication Number	Publication Date
SK9142000A3 true SK9142000A3 (en)	2000-11-07

Family

ID=10823780

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK914-2000A SK9142000A3 (en)	1997-12-17	1998-12-16	Tetrahydro isoquinolinyl carboxamide compounds, preparation thereof, pharmaceutical composition containing them and their use

Country Status (30)

Country	Link
US (1)	US6248754B1 (fr)
EP (1)	EP1042296B1 (fr)
JP (1)	JP2002508360A (fr)
KR (1)	KR20010033194A (fr)
CN (1)	CN1125052C (fr)
AP (1)	AP2000001832A0 (fr)
AR (1)	AR014942A1 (fr)
AT (1)	ATE260258T1 (fr)
AU (1)	AU744451B2 (fr)
BG (1)	BG104607A (fr)
BR (1)	BR9813642A (fr)
CA (1)	CA2315079A1 (fr)
CO (1)	CO5080731A1 (fr)
DE (1)	DE69821988T2 (fr)
EA (1)	EA200000657A1 (fr)
ES (1)	ES2216333T3 (fr)
GB (1)	GB9726695D0 (fr)
HU (2)	HUP0000987A3 (fr)
ID (1)	ID24810A (fr)
IL (1)	IL136382A0 (fr)
MA (1)	MA26583A1 (fr)
NO (1)	NO315649B1 (fr)
NZ (1)	NZ504706A (fr)
OA (1)	OA11526A (fr)
PE (1)	PE20000006A1 (fr)
PL (1)	PL341222A1 (fr)
SK (1)	SK9142000A3 (fr)
TR (1)	TR200001791T2 (fr)
WO (1)	WO1999031068A1 (fr)
ZA (1)	ZA9811503B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010016657A1 (en) *	1997-03-18	2001-08-23	Smithkline Beecham P.L.C.	Substituted isoquinoline derivatives and their use as anticonvulsants
WO1999016752A1 (fr) *	1997-09-30	1999-04-08	Molecular Designs International, Inc.	AGONISTES DE β3-ADRENORECEPTEURS, COMPOSITIONS D'AGONISTES ET PROCEDES D'UTILISATION
GB9915589D0 (en) *	1999-07-02	1999-09-01	Smithkline Beecham Plc	Novel compounds
WO2001042224A1 (fr) *	1999-12-09	2001-06-14	Mitsubishi Pharma Corporation	Derives carboxyamido
US6593341B2 (en)	2001-03-29	2003-07-15	Molecular Design International, Inc.	β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
US7173032B2 (en)	2001-09-21	2007-02-06	Reddy Us Therapeutics, Inc.	Methods and compositions of novel triazine compounds
US6596734B1 (en)	2002-10-11	2003-07-22	Molecular Design International, Inc.	Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
US7119214B2 (en) *	2004-04-13	2006-10-10	Cephalon France	Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
GB0619176D0 (en) *	2006-09-29	2006-11-08	Lectus Therapeutics Ltd	Ion channel modulators & uses thereof
TWI459947B (zh)	2007-06-26	2014-11-11	Otsuka Pharma Co Ltd	苯并氮呯化合物及藥學製劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4022900A (en) *	1970-09-09	1977-05-10	Marion Laboratories, Inc.	Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
HUP9902166A3 (en)	1996-06-17	2001-01-29	Smithkline Beecham Plc	Substituted benzamide derivatives having anticonvulsant activity, preparation and use thereof, pharmaceutical compositions containing these compounds
IL131756A0 (en) *	1997-03-18	2001-03-19	Smithkline Beecham Plc	Substituted isoquinoline derivatives and their use as anticonvulsants

1997
- 1997-12-17 GB GBGB9726695.1A patent/GB9726695D0/en not_active Ceased
1998
- 1998-03-16 HU HU0000987A patent/HUP0000987A3/hu unknown
- 1998-12-15 ZA ZA9811503A patent/ZA9811503B/xx unknown
- 1998-12-15 MA MA25393A patent/MA26583A1/fr unknown
- 1998-12-16 HU HU0004663A patent/HUP0004663A3/hu unknown
- 1998-12-16 EA EA200000657A patent/EA200000657A1/ru unknown
- 1998-12-16 US US09/581,647 patent/US6248754B1/en not_active Expired - Fee Related
- 1998-12-16 CA CA002315079A patent/CA2315079A1/fr not_active Abandoned
- 1998-12-16 CN CN98813570A patent/CN1125052C/zh not_active Expired - Fee Related
- 1998-12-16 AT AT98960040T patent/ATE260258T1/de not_active IP Right Cessation
- 1998-12-16 JP JP2000538995A patent/JP2002508360A/ja active Pending
- 1998-12-16 PE PE1998001234A patent/PE20000006A1/es not_active Application Discontinuation
- 1998-12-16 WO PCT/GB1998/003785 patent/WO1999031068A1/fr not_active Application Discontinuation
- 1998-12-16 OA OA1200000180A patent/OA11526A/en unknown
- 1998-12-16 AP APAP/P/2000/001832A patent/AP2000001832A0/en unknown
- 1998-12-16 BR BR9813642-9A patent/BR9813642A/pt not_active Application Discontinuation
- 1998-12-16 TR TR2000/01791T patent/TR200001791T2/xx unknown
- 1998-12-16 SK SK914-2000A patent/SK9142000A3/sk unknown
- 1998-12-16 NZ NZ504706A patent/NZ504706A/xx unknown
- 1998-12-16 AU AU15724/99A patent/AU744451B2/en not_active Ceased
- 1998-12-16 EP EP98960040A patent/EP1042296B1/fr not_active Expired - Lifetime
- 1998-12-16 ID IDW20001157A patent/ID24810A/id unknown
- 1998-12-16 AR ARP980106398A patent/AR014942A1/es not_active Application Discontinuation
- 1998-12-16 IL IL13638298A patent/IL136382A0/xx unknown
- 1998-12-16 DE DE69821988T patent/DE69821988T2/de not_active Expired - Fee Related
- 1998-12-16 PL PL98341222A patent/PL341222A1/xx unknown
- 1998-12-16 KR KR1020007006579A patent/KR20010033194A/ko not_active Withdrawn
- 1998-12-16 ES ES98960040T patent/ES2216333T3/es not_active Expired - Lifetime
- 1998-12-17 CO CO98075174A patent/CO5080731A1/es unknown
2000
- 2000-06-16 NO NO20003142A patent/NO315649B1/no not_active IP Right Cessation
- 2000-07-13 BG BG104607A patent/BG104607A/bg unknown

Also Published As

Publication number	Publication date
IL136382A0 (en)	2001-06-14
US6248754B1 (en)	2001-06-19
DE69821988D1 (de)	2004-04-01
CN1125052C (zh)	2003-10-22
NO315649B1 (no)	2003-10-06
KR20010033194A (ko)	2001-04-25
HUP0004663A3 (en)	2002-10-28
TR200001791T2 (tr)	2000-12-21
NZ504706A (en)	2002-11-26
EA200000657A1 (ru)	2000-12-25
HUP0000987A2 (hu)	2000-09-28
AU744451B2 (en)	2002-02-21
PE20000006A1 (es)	2000-03-01
CN1284946A (zh)	2001-02-21
ID24810A (id)	2000-08-24
ATE260258T1 (de)	2004-03-15
AU1572499A (en)	1999-07-05
HUP0004663A2 (hu)	2001-05-28
EP1042296B1 (fr)	2004-02-25
CA2315079A1 (fr)	1999-06-24
ZA9811503B (en)	2000-06-15
BR9813642A (pt)	2000-10-17
NO20003142L (no)	2000-06-16
AP2000001832A0 (en)	2000-06-30
HUP0000987A3 (en)	2000-10-30
OA11526A (en)	2004-02-09
WO1999031068A1 (fr)	1999-06-24
EP1042296A1 (fr)	2000-10-11
BG104607A (bg)	2001-02-28
MA26583A1 (fr)	2004-12-20
DE69821988T2 (de)	2005-01-05
CO5080731A1 (es)	2001-09-25
NO20003142D0 (no)	2000-06-16
ES2216333T3 (es)	2004-10-16
GB9726695D0 (en)	1998-02-18
JP2002508360A (ja)	2002-03-19
AR014942A1 (es)	2001-04-11
PL341222A1 (en)	2001-03-26

Publication	Publication Date	Title
JP3690423B2 (ja)	2005-08-31	置換イソキノリン誘導体およびその抗痙攣薬としての使用
US20030144320A1 (en)	2003-07-31	Substituted isoquinoline derivatives and their use as anticonvulsants
SK9142000A3 (en)	2000-11-07	Tetrahydro isoquinolinyl carboxamide compounds, preparation thereof, pharmaceutical composition containing them and their use
SK126799A3 (en)	2000-05-16	Isoquinolyl-benzamide derivatives, process for their production, pharmaceutical composition containing them and their use
EP1200409B1 (fr)	2004-02-25	Derives d' isoquinoleine substituee et leur utilisation comme anticonvulsants
JP2001523678A (ja)	2001-11-27	イソキノリン誘導体およびその治療用途
CZ2001436A3 (cs)	2001-08-15	Nové sloučeniny
US6410555B1 (en)	2002-06-25	Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
US6492378B1 (en)	2002-12-10	Substituted isoquinoline derivatives and their use as anticonvulsivants
CZ20002221A3 (cs)	2000-11-15	Substituované deriváty isochinolinu a jejich použití jako antikonvulziva
WO2000008022A1 (fr)	2000-02-17	Derives uree
MXPA99008583A (en)	2000-02-02	Substituted isoquinoline derivatives and their use as anticonvulsants
KR20000016715A (ko)	2000-03-25	치환된 벤즈아미드 유도체 및 항경련제로서의그의 용도ㅔ